Indolent Lymphoma - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 156

Indolent Lymphoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Indolent Lymphoma - Pipeline Review, H1 2012', provides an overview of the Indolent Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. 'Indolent Lymphoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Indolent Lymphoma.
- A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Indolent Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indolent Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Indolent Lymphoma Therapeutic Products under Development, Key Players in Indolent Lymphoma Therapeutics, Indolent Lymphoma Pipeline Overview, Indolent Lymphoma Pipeline, Indolent Lymphoma Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Indolent Lymphoma Overview
Therapeutics Development
An Overview of Pipeline Products for Indolent Lymphoma
Indolent Lymphoma Therapeutics under Development by Companies
Indolent Lymphoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Indolent Lymphoma Therapeutics – Products under Development by Companies
Indolent Lymphoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Indolent Lymphoma Therapeutics Development
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Sanofi-Aventis
GlaxoSmithKline plc
Gilead Sciences, Inc.
Cephalon, Inc.
Pfizer Inc.
Cell Therapeutics, Inc.
Celgene Corporation
Accentia Biopharmaceuticals, Inc.
Mundipharma International Limited
S-BIO Pte Ltd
Astellas Pharma GmbH
Indolent Lymphoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RG7159 - Drug Profile
Pacritinib - Drug Profile
BiovaxID - Drug Profile
Bendamustine Hydrochloride - Drug Profile
GS-1101 - Drug Profile
Rituximab + Gemcitabine + Oxaliplatin - Drug Profile
Rituxan + BEAM + Autologous Stem Cell Transplantation - Drug Profile
PS-341 + Alvocidib - Drug Profile
VR-CHOP - Drug Profile
RAD001 + Velcade - Drug Profile
Rituximab - Drug Profile
Velcade + Rituximab - Drug Profile
Rituximab + Dexamethasone - Drug Profile
Vorinostat - Drug Profile
CMC-544 - Drug Profile
Treanda + Rituxan - Drug Profile
GS 1101 + Bendamustine + Rituximab - Drug Profile
GS 1101 + Bendamustine - Drug Profile
GS-1101 + Rituximab - Drug Profile
RG7159 + Bendamustine - Drug Profile
Arzerra + Bendamustine - Drug Profile
RG7159 + CHOP - Drug Profile
Pixuvri + Fludarabine + Dexamethasone + Rituximab - Drug Profile
Zevalin + Rituximab - Drug Profile
Dolastatin 10 - Drug Profile
Velcade + BEAM + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile
Vorinostat + Rituximab - Drug Profile
Proleukin + Cyclophosphamide + Therapeutic Autologous Lymphocytes - Drug Profile
Tumor Derived Immunoglobulin Idiotype With Keyhole Limpet Hemocyanin Conjugate Vaccine + Sargramostim + Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile
Treanda + Ofatumumab - Drug Profile
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile
Rituximab + THP-COP - Drug Profile
Interleukin-4 - Drug Profile
Rituxan + Doxil - Drug Profile
Rituximab + Velcade + Cladribine - Drug Profile
Rituximab + Bortezomib + Cyclophosphamide + Prednisone - Drug Profile
Pegfilgrastim + Rituximab - Drug Profile
Recombinnat Interferon Alfa + Cyclophosphamide + Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate - Drug Profile
Rituximab + PS-341 + Fludarabine - Drug Profile
Rituximab + Zevalin - Drug Profile
Proleukin + Therapeutic Autologous Lymphocytes + Cyclophosphamide + Prednisone + Vincristine Sulfate - Drug Profile
Rituximab + Lenalidomide - Drug Profile
Rituximab + Bendamustine + Obatoclax - Drug Profile
Rituximab + Bendamustine - Drug Profile
Ofatumumab - Drug Profile
Bendamustine - Drug Profile
Revlimid + Rituxan - Drug Profile
Ofatumumab - Drug Profile
Zevalin + Rituxan - Drug Profile
TRU-016 + Rituximab + Bendamustine - Drug Profile
RO5072759 + Chemotherapy - Drug Profile
Allogeneic Haematopoietic Stem Cell Transplantation + Fludarabine + Radiation Therapy - Drug Profile
GS 1101 + Ofatumumab - Drug Profile
GS 1101 + Fludarabine - Drug Profile
SAR245409 + Rituximab - Drug Profile
SAR245409 + Bendamustine + Rituximab - Drug Profile
SAR245409 + Bendamustine - Drug Profile
Fludarabine + Cyclophosphamide - Drug Profile
Indolent Lymphoma Therapeutics – Drug Profile Updates
Indolent Lymphoma Therapeutics – Discontinued Products
Indolent Lymphoma Therapeutics - Dormant Products
Indolent Lymphoma – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Indolent Lymphoma, H1 2012
Products under Development for Indolent Lymphoma – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Abbott Laboratories, H1 2012
Sanofi-Aventis, H1 2012
GlaxoSmithKline plc, H1 2012
Gilead Sciences, Inc., H1 2012
Cephalon, Inc., H1 2012
Pfizer Inc., H1 2012
Cell Therapeutics, Inc., H1 2012
Celgene Corporation, H1 2012
Accentia Biopharmaceuticals, Inc., H1 2012
Mundipharma International Limited, H1 2012
S-BIO Pte Ltd, H1 2012
Astellas Pharma GmbH, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Indolent Lymphoma Therapeutics – Drug Profile Updates
Indolent Lymphoma Therapeutics – Discontinued Products
Indolent Lymphoma Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Indolent Lymphoma, H1 2012
Products under Development for Indolent Lymphoma – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Lymphoma - Pipeline Review, H2 2012
• Indolent Lymphoma - Pipeline Review, Q4 2010
• Non-Hodgkin Lymphoma - Pipeline Review, H2 2012
• Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
• Chronic Lymphoblastic Lymphoma - Pipeline Review, H2 2012
• Thrombocytopenia - Pipeline Review, H1 2013
• Cystic Fibrosis - Pipeline Review, H1 2013
• Macular Degeneration - Pipeline Review, H1 2013
• Wounds - Pipeline Review, H1 2013
• Renal Failure - Pipeline Review, H1 2013